Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.

Amgen and Abilita Bio have inked a research deal, focusing on developing drugs for challenging membrane protein targets.

The deal sees Novartis join GlaxoSmithKline, Merck and Pfizer on the list of companies partnered with the antibody discovery shop.

A team led by the Wyss Institute has created reversible platelets that they say may not only reduce blood clots but might also prevent cancer from spreading.

Hologic launched management software for its mammography machines that can predict the failure of X-ray hardware and help schedule early replacements.

Charles River has added another string to its early-stage R&D bow by acquiring preclinical services firm Citoxlab for $510 million in cash.

The deal sees Sygnature take a stake in Pathios in part payment for its involvement in the Oxford-based biotech’s hit-to-lead program.

The panel’s decision to back the ketamine-like drug tees J&J up to win approval for one of the most notable antidepressants in decades.